The United States spends more on healthcare than any other country, and it’s not particularly close. In 2024, national health expenditures hit $5.3 trillion, or about $15,474 per person, consuming 18% of the entire economy. That’s roughly twice what other wealthy nations spend per person, yet Americans don’t use more medical services or live longer as a result. The gap comes down to higher prices at almost every level of the system, compounded by administrative complexity, consolidation among hospitals, and a payment structure that rewards volume over results.
Higher Prices, Not More Care
The single biggest reason the U.S. spends so much is that everything costs more. A widely cited analysis in JAMA found that Americans use healthcare at roughly the same rates as people in other high-income countries, but pay dramatically higher prices for the same services. This applies to hospital stays, doctor visits, prescription drugs, and medical devices. The old summary holds up well: it’s the prices, stupid.
Physician compensation is one clear example. The average U.S. physician earns about $316,000 per year, compared to $183,000 in Germany and $138,000 in the U.K. Specialists see even wider gaps. Male specialists in the U.S. average $376,000 annually, nearly double the $194,000 their German counterparts earn. These salaries reflect a combination of factors: longer and more expensive medical training, higher student debt loads, and a market where hospitals and health systems compete aggressively for talent. Primary care physicians in the U.S. earn around $242,000, also the highest of any country surveyed.
Brand-Name Drug Prices Dwarf Global Averages
Prescription drugs are another major cost driver. U.S. prices for brand-name drugs run about 308% of prices in other countries, even after accounting for the rebates that drug companies pay back to insurers and pharmacy benefit managers. Before those rebates, the sticker price sits at 422% of international levels. The gap exists almost entirely in brand-name medications. Unbranded generics, which make up 90% of prescriptions filled in the U.S., actually cost less here, averaging 67% of prices elsewhere.
The reason for this disparity is structural. Most other wealthy countries have government agencies that negotiate drug prices directly with manufacturers or set reference prices that cap what can be charged. The U.S. has historically left pricing to the market, giving manufacturers significant latitude to set and raise prices. Medicare only recently gained limited authority to negotiate prices on a small number of drugs, a power that most peer nations have exercised for decades.
Administrative Costs Eat Up Billions
Running the U.S. healthcare system is extraordinarily expensive. Administrative costs, meaning the money spent on planning, regulating, billing, coding, and managing insurance claims, account for about 8% of total healthcare spending. In other high-income countries, that figure ranges from 1% to 3%.
This overhead stems from the fragmented nature of American health insurance. Hospitals and doctor’s offices deal with dozens of private insurers, each with different coverage rules, preauthorization requirements, and billing codes. A single physician practice may employ more billing staff than clinical staff. On the insurer side, companies spend heavily on claims processing, marketing, and utilization review (the process of deciding whether to approve or deny a requested treatment). None of this clinical complexity exists in countries with a single payer or a small number of tightly regulated insurers using standardized forms.
Hospital Consolidation Drives Up Prices
Over the past two decades, hospitals across the country have been merging into larger and larger systems. When a hospital system acquires competitors, even in different geographic markets, it gains negotiating leverage over insurers. The result is higher prices without improvements in care quality.
Research tracking these mergers found that six years after an acquisition, the acquiring hospital’s prices had risen nearly 13% relative to hospitals that stayed independent. For large systems that made four or more acquisitions, prices climbed over 16%. When a smaller hospital was absorbed by a larger system, the price increases were even steeper, reaching 22% or more. Perhaps most telling, nearby competing hospitals also raised their prices by about 8% after a merger in their area, suggesting that consolidation reduces competitive pressure across entire regions. Studies found no corresponding improvement in mortality or readmission rates for conditions like heart attacks, heart failure, or pneumonia.
A Payment System That Rewards More, Not Better
The traditional way American healthcare gets paid for is called fee-for-service: providers bill separately for every test, procedure, office visit, and scan. The more services rendered, the more revenue generated. This creates a built-in incentive to do more, whether or not additional testing or treatment improves outcomes.
This structure helps explain why the U.S. leads the world in high-cost imaging. Americans get more CT scans, MRIs, and PET scans per capita than nearly any other country, with a combined total exceeding 360 exams per 1,000 people. While some of this imaging catches important diagnoses, a portion reflects the financial incentive to order tests rather than watch and wait. Value-based care models, which pay providers based on patient outcomes rather than the number of services delivered, have been introduced as an alternative. But fee-for-service still dominates much of the system, particularly in specialty care.
Chronic Disease Carries an Enormous Price Tag
The U.S. has high rates of chronic conditions like diabetes, heart disease, and obesity, and managing these diseases is expensive. According to the CDC, 90% of the nation’s $4.9 trillion in annual healthcare expenditures go toward treating people with chronic and mental health conditions. This isn’t just a reflection of an aging population. Americans develop chronic diseases earlier and at higher rates than people in many peer countries, partly due to differences in diet, physical activity, and access to preventive care.
Chronic disease spending is especially difficult to control because these conditions require ongoing management: regular doctor visits, daily medications, periodic lab work, and occasional hospitalizations. A person with well-managed Type 2 diabetes still costs the system thousands of dollars a year. When conditions go poorly managed, often because of gaps in insurance coverage or inability to afford medications, the costs spike through emergency room visits and hospital admissions that could have been prevented.
Defensive Medicine Adds Billions
The U.S. malpractice system creates a secondary cost pressure. Physicians who fear being sued for missing a diagnosis often order extra tests and imaging as a form of legal protection, a practice known as defensive medicine. These additional tests are estimated to cost roughly $46 billion per year. While that figure is modest relative to total spending, it compounds the broader pattern of overuse baked into fee-for-service payment. It also contributes to a culture of “more is better” that pervades American medicine in ways that are difficult to quantify.
Why It All Adds Up
No single factor explains why American healthcare costs so much. The spending gap is the result of multiple reinforcing dynamics: prices for drugs, labor, and hospital services that far exceed international norms; an insurance system that generates massive administrative waste; hospital consolidation that reduces competition; a payment model that incentivizes volume; and a population carrying a heavy burden of chronic disease. Other wealthy countries have managed to control costs not through any one clever policy, but by regulating prices, simplifying administration, and negotiating collectively in ways the U.S. system, by design, largely does not.